237 related articles for article (PubMed ID: 15806137)
1. Characterization of lymphoblast mitochondria from patients with Barth syndrome.
Xu Y; Sutachan JJ; Plesken H; Kelley RI; Schlame M
Lab Invest; 2005 Jun; 85(6):823-30. PubMed ID: 15806137
[TBL] [Abstract][Full Text] [Related]
2. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography.
Acehan D; Xu Y; Stokes DL; Schlame M
Lab Invest; 2007 Jan; 87(1):40-8. PubMed ID: 17043667
[TBL] [Abstract][Full Text] [Related]
4. Phosphokinome Analysis of Barth Syndrome Lymphoblasts Identify Novel Targets in the Pathophysiology of the Disease.
Agarwal P; Cole LK; Chandrakumar A; Hauff KD; Ravandi A; Dolinsky VW; Hatch GM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002286
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid abnormalities in children with Barth syndrome.
Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
[TBL] [Abstract][Full Text] [Related]
6. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
7. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
8. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
9. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
10. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
11. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome.
Claypool SM; Boontheung P; McCaffery JM; Loo JA; Koehler CM
Mol Biol Cell; 2008 Dec; 19(12):5143-55. PubMed ID: 18799610
[TBL] [Abstract][Full Text] [Related]
12. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
13. Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
Bozelli JC; Lu D; Atilla-Gokcumen GE; Epand RM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158677. PubMed ID: 32126285
[TBL] [Abstract][Full Text] [Related]
14. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
15. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.
Hsu P; Liu X; Zhang J; Wang HG; Ye JM; Shi Y
Autophagy; 2015 Apr; 11(4):643-52. PubMed ID: 25919711
[TBL] [Abstract][Full Text] [Related]
16. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
17. Cardiolipin deficiency leads to the destabilization of mitochondrial magnesium channel MRS2 in Barth syndrome.
Joshi A; Gohil VM
Hum Mol Genet; 2023 Dec; 32(24):3353-3360. PubMed ID: 37721533
[TBL] [Abstract][Full Text] [Related]
18. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of mitochondrial oxodicarboxylate carrier (ODC1) preserves oxidative phosphorylation in a yeast model of Barth syndrome.
de Taffin de Tilques M; Tribouillard-Tanvier D; Tétaud E; Testet E; di Rago JP; Lasserre JP
Dis Model Mech; 2017 Apr; 10(4):439-450. PubMed ID: 28188263
[TBL] [Abstract][Full Text] [Related]
20. A Drosophila model of Barth syndrome.
Xu Y; Condell M; Plesken H; Edelman-Novemsky I; Ma J; Ren M; Schlame M
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11584-8. PubMed ID: 16855048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
